This is an open-label, single-arm, multicenter, pilot study of pembrolizumab, exemestane, and
leuprolide for subjects being resistant for front-line hormonal therapy for inoperable
locally advanced or metastatic hormonal receptor positive (HR+)/ Human epidermal growth
factor receptor 2 (HER2) negative breast cancer. All the patients will be included in the
final tolerability and preliminary efficacy analysis. The efficacy objectives including PFS,
overall response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR).
Adverse effects will be recorded according to CTCAE v4.0.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.